We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (4718)2/2/2018 11:52:48 AM
From: richardred  Respond to of 6155
Added to CPB today.

To: richardred who wrote (4718)6/20/2018 10:45:51 AM
From: richardred  Respond to of 6155
RE- ANIK speculation- Big disappointment on Cingal. CINGAL failed to demonstrate a statistically significant reduction in knee pain compared to triamcinolone hexacetonide alone. The company also had some earlier foul ups with product recalls. The only near term positive I can see. The company can now complete their 2018 share buyback program. I'd like to see where the dust settles before I possibly re-enter.

Message #4718 from richardred at 1/31/2018 12:26:48 PM

Added to CPB today & ASYS Sold out of TT 2018 SITT Pick ANIK. Had a nice run up from my purchase price. Maybe a re-look later. Still regard it as having high speculative appeal.

To: richardred who wrote (4709)1/29/2018 10:36:11 AM
From: richardred1 Recommendation of 4888
Sold some ANIK today on a big run up from my purchase price.